Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's Time to Get Serious--No More Mr. Nice Guy
Dear Loyal and Stalwart Supporters of GenoMed,
You are one of the best assets of the company.
It's time for us to earn revenues.
It's also time for guerilla marketing.
So if you see any independent retail pharmacies in your neighborhood, could you please send me their telephone number?
It's taken me 11 years, but I've finally figured out who our business partners are: independent retail pharmacists who are trying to survive financially. They're being squeezed by the chain drugstores, as well as the mail-order pharmacy benefit managers (PBMs). We can increase their revenues, and they can help us prevent 90% of dialysis (http://tinyurl.com/nodialysis).
So please send me the names and locations of any independent retail pharmacies you happen to drive past.
Thanks!
No more Mr. Nice Guy. It's time for us to get serious about public health.
Best regards,
Dave Moskowitz MD
CEO & Chief Medical Officer
GenoMed, Inc.
www.genomed.com
tel. 314.983.9938
dwmoskowitz@genomed.com
GMED (on OTC Pink Sheets)
GenoMed Partners with Jennifer's Pharmacy in Clayton, MO
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
Jennifer Rich RPh
CEO, Jennifer's Pharmacy
Jennifer@jenniferspharmacy.com
Tel. 314.862.7400
ST. LOUIS—July 8, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it has partnered with Jennifer's Pharmacy of Clayton, Missouri, a suburb of St. Louis as part of GenoMed's plan to make the US dialysis-free by 2014 (http://tinyurl.com/nodialysis).
Jennifer's Pharmacy will educate its customers with type 2 diabetes, high blood pressure, as well as emphysema about GenoMed's Clinical Outcomes Improvement Program (COIP®).
David W. Moskowitz, MD FACP, GenoMed's CEO and Chief Medical Officer, said "Education is key if we are to prevent kidney failure. We're delighted that Jennifer's Pharmacy is as eager as we are to serve their clients' health needs. We look forward to a long and fruitful association with Jennifer's Pharmacy and their clients."
Said Jennifer Rich, RPh, CEO of Jennifer's Pharmacy, "We're happy to do our part to help our customers live a healthier and longer life. Being healthy also means preventing future health problems. We are excited to be able to work with Dr. Moskowitz."
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™ in the world, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere on earth. Please contact Dr. Moskowitz (see above for contact info) if you have one of these diseases.
About Jennifer's Pharmacy & Soda Shoppe
As the only independent retail pharmacy in the city of Clayton, Missouri, Jennifer's Pharmacy has already attracted a strong and loyal following.
House of Lords Issues Report on Genomics; GenoMed Part of It
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
ST. LOUIS—July 7, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it is part of a white paper which the House of Lords Subcommittee on Genomics and Medicine issued today.
The House of Lords Committee on Science and Technology, Subcommittee on Genomic Medicine, issued a white paper today which encourages the National Health Service to make use of the advances in genomic medicine sooner rather than later (http://tinyurl.com/HouseOfLordsGenomicReport).
GenoMed contributed to this report (http://tinyurl.com/GMEDwhitepaper), identifying specific ways in which any patient population could take advantage of what's already known about genomic medicine.
David W. Moskowitz, MD FACP, GenoMed's CEO, said "We're delighted to have our contribution included in the House of Lords' White Paper. As the pioneer in bringing genomic medicine to the clinic, GenoMed is in a unique position to improve patient outcomes and lower healthcare costs. Our program to eliminate dialysis around the world by 2014 is a perfect example (http://tinyurl.com/nodialysis)."
Added Dr. Moskowitz, "I hope the British National Health Service, as well as Medical Directors in charge of patient populations everywhere, read the House of Lords' White Paper. Together, we can make our dream of eliminating 90% of kidney failure in 5 years a reality."
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™ in the world, GenoMed aims to arrest diabetes, hypertension, and emphysema globally. No genotyping is required for these diseases. Please contact Dr. Moskowitz if you have one of these diseases.
About the House of Lords
The House of Lords began phasing out life-time, hereditary membership under the leadership of Prime Minister Tony Blair, and replacing peers with experts who had achieved distinction in their respective fields. This has enabled the House of Lords to provide expert advice to the House of Commons and the Executive Branch of British government, including the National Health Service.
GenoMed forms international partnerships for diabetes prevention
St. Louis Business Journal - by Angela Mueller
Friday, June 26, 2009
GenoMed Inc. is partnering with three companies in the Philippines to help bring a diabetes prevention and management program to the country.
GenoMed, a St. Louis-based medical genomics company, is teaming up with Internet services firm LaSalTech, telecommunications firm Globe Telecom Inc., and retail drug company Mercury Drug to help Filipino patients manage and prevent diabetes via a text messaging and cell phone service. For a flat fee of about $20 a year, patients will be able to be in weekly text and e-mail contact with physicians who would help them use a disease management program developed by GenoMed to help diabetic and potentially diabetic patients avoid dialysis.
Dr. David Moskowitz, chairman and CEO of GenoMed, said he expects the service to launch around July 1.
Moskowitz initially connected with the Filipino partner companies via the LinkedIn social media site. He mentioned an upcoming trip to Malaysia on his LinkedIn profile, and a dialysis nurse from the Philippines contacted him and helped connect him with Rolando Dizon, chairman of LaSalTech.
UPDATE (Philippines)/CEO Q&A from the company's web site:
In light of the 10 + 10 and free in five announcements, please provide an update on progress in the Philippines so that we better understand the potential there.
Thank you.
We had been hoping to get buy-in from several big hitters--a telecom company, the major drugstore chain, as well as a medical school. None of them has been forthcoming, despite great initial promise. It may be premature to move on, but I am--lives are at stake. So we're now going after independent retail pharmacists in the Philippines as we are in every other country. They're the ideal marketers for the following reasons:
1. They're already in the business of dispensing medications, unlike telecom companies which have never been involved in healthcare before.
2. They're struggling to survive against the big chains and the mail-order pharmacies.
3. Being small, the owner can make his/her own decisions, and not defer to an army of lawyers, as happened at the telecom company.
Thanks for your excellent question.
Best regards,
Dave Moskowitz MD
CEO, GenoMed
*Swine flu has infected as many as 1million Americans
*The U.S. count includes 3,065 hospitalizations and 127 deaths.
By MIKE STOBBE, AP Medical Writer Mike Stobbe, Ap Medical Writer – 20 mins ago
http://news.yahoo.com/s/ap/20090625/ap_on_he_me/us_med_swine_flu
Flu shuts down more schools
MANILA, Philippines
Updated June 25, 2009 12:00 AM
http://www.philstar.com/Article.aspx?articleId=480788&publicationSubCategoryId=63
GenoMed Partners with Retail Pharmacy in Cameroon, Central Africa
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
Donald Njikam PharmD
CEO, Kaya Holdings
donald.njikam@gmail.com
Tel. 813.546.2209 (U.S.)
+237.22.31.49.08 (Cameroon)
ST. LOUIS—June 23, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it has partnered with Pharmacie Principale, a retail pharmacy in Yaounde, the capital city of Cameroon, in Central Africa.
Pharmacie Principale will educate its customers with type 2 diabetes, high blood pressure, and emphysema about GenoMed's Clinical Outcomes Improvement Program (COIP®).
In addition, Pharmacie Principale will tell patients about GenoMed's Phase IV trials for serious diseases such as metastatic cancer, sickle cell disease, HIV, ebola, dengue, etc.
David W. Moskowitz, MD FACP, GenoMed's CEO and Chief Medical Officer, said "Education is key. We're delighted that Pharmacie Principale is as eager as we are to serve their clients' health needs. We look forward to a long and fruitful association with Pharmacie Principale and their clients."
Said Donald Njikam, PharmD, CEO of Kaya Holdings, which owns Pharmacie Principale, "We're excited to use our pharmacy to educate our customers about state-of-the-art healthcare techniques. Retail pharmacies are a tremendous resource. So far, GenoMed is the only company I know of that recognizes their full potential."
Added Dr. Njikam, "I'm surprised that Dr. Moskowitz's published results have received such little attention in the US. His techniques are simple enough for any pharmacy to implement. We are collaborating closely by email on each patient in a form of tele-medicine and by so doing making expert health care consultations easily accessible to patients in the developing world at a fraction of the cost."
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™ in the world, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere on earth. Please contact Dr. Moskowitz if you have one of these diseases.
About Kaya Holdings/Pharmacie Principale
Pharmacie Principale is an independent retail pharmacy in the capital city of Yaounde, Cameroon, Central Africa. National law prevents anyone from owning more than a single pharmacy, so there are no pharmacy chains in Cameroon. Pharmacie Principale wants to make available the best healthcare possible to its customers by providing the same cutting edge therapy available to US patients delivered by U.S based specialists through telemedicine.
TMI proudly supports Genomed, Inc. and his CEO's remarkable initiative providing free on-line medical consultation.
http://www.technicalmedical.com/en/tmi_news.html
BIT Life Sciences' 2nd Annual World Summit of Antivirals 2009
Full Scientific Program
http://www.bioevent.cn/articledetail.asp?meetingid=1378&classid=869
Theme: Meeting the Health Challenges in the Globalization
Time: July 18-20, 2009
Place: Lobby of Beijing International Convention Center, Beijing, China July 17, 2009
Track3-4: Antiviral Immunomodulator/Immunostimu-lants and Other Protein Therapeutic
Time: July 20, 2009, Monday, 13:30-17:30
Session Chair: Dr. David W. Moskowitz, Chairman, CEO & Chief Medical Officer, GenoMed, Inc., USA
Title: A General ViralAntidote
Can you guess what is coming next?...$ ."15"-"20"??(:?)
GenoMed Launches "10 + 10" Global Marketing Campaign
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
ST. LOUIS—June 19, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it is launching a world-wide marketing campaign to increase its clients' lifespan by 10 years while rewarding its marketers with 10% of the patient revenues they bring in.
GenoMed published a series of papers in 2002-2004 showing that overactivity of angiotensin I-converting enzyme (ACE) was behind three-quarters of common diseases—heart disease, almost all cancers, autoimmune diseases, even some infectious diseases, etc. The company's CEO, David Moskowitz MD FACP, was able to reverse early stage kidney failure due to diabetes or high blood pressure, the two main causes of heart disease. It's quite likely that heart disease itself could be reversed. Thus, it is reasonable to estimate that proper inhibition of tissue ACE, if begun in time, could add a decade of life to patients.
GenoMed has published in the peer-reviewed medical literature a safe and effective way to inhibit tissue ACE. There is no medical or legal impediment to applying this method to any patient population on earth.
The problem has been to communicate these findings to the patients who need to know-- the world's 2 billion adults—at a time when public health no longer takes care of patients, and medicine has completely lost its nerve.
David W. Moskowitz, MD FACP, GenoMed's CEO and Chief Medical Officer, said "Education is key. There's no point finding the major aging gene for all vertebrates—which we believe ACE to be—and have our discovery still be a secret seven years later. We need help getting the word out. In a word, we need a global marketing campaign. We can't rely on public health officials, so we'll go to the grass roots."
Dr. Moskowitz continued, "We ask that people refer their friends and family who have high blood pressure, diabetes, or emphysema. We'll work with the patient for two months or so, at a cost of $75 per month ($7.50/month for poor people). That should get the patient on the right dose of the right ACE inhibitor and start them on the right path to live an extra 10 years."
Dr. Moskowitz ended by saying, "In return, we commit to paying our marketers 10% of what we earn as a result of their efforts. In the First World, people can expect to make an average of $15 per referral; in the Third World, $1.50. So you not only do right by your family and friends, you make a little money on the side. And who couldn't use a little extra money nowadays?"
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™ in the world, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere on earth. Please contact Dr. Moskowitz if you have one of these diseases.
GenoMed Launches "Dialysis-Free in Five" Campaign
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
ST. LOUIS—June 18, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it is launching a world-wide campaign to eradicate kidney dialysis by 2014.
GenoMed published in 2002 how to reverse early-stage kidney failure in patients with type 2 diabetes or high blood pressure. Globally, these two diseases cause over 90% of kidney failure that requires dialysis with the kidney machine.
David W. Moskowitz, MD FACP, GenoMed's CEO and Chief Medical Officer, said "Education is all that's needed to eliminate 90% of new cases of kidney failure. We have to get to patients with diabetes or high blood pressure before their serum creatinine is 2. Most patients have no idea what their serum creatinine is. But it's more important than their cholesterol. You've already lost half your kidney function when your serum creatinine is 2 [mg/dl]. In four years, unless you go on our program, you'll be on dialysis."
Dr. Moskowitz continued, "There are currently 300,000 people on dialysis in the US. Every year, 100,000 more Americans go on dialysis. If we could take care of the 80 million Americans with diabetes or high blood pressure, we could cut this number down to 10,000 new patients a year. With 25,000 kidney transplants a year in the US, there'd be more than enough kidneys available for every one of these patients to get a kidney transplant. That's why our slogan is 'Dialysis-free in Five.'"
Dr. Moskowitz ended by saying, "We call on everybody seeing patients, especially primary care providers and pharmacists, to help us reach our goal of 'Free in Five.' All it takes is a blood pressure cuff and our recipe. The drugs we use are generic and every drugstore carries them. The only thing lacking is awareness. Fortunately, in the Internet Age, everybody's message can finally be heard."
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere on earth. Please contact Dr. Moskowitz if you have one of these diseases.
Medical Alerts and News Portal Philippines
http://medalerts.blogspot.com/#uds-search-results
Tuesday, June 17, 2009
A report on ABS CBN states that a new AH1N1 strain has been reported in Brazil. The new strain called A/Sao Paulo/1454/H1N1 by the Adolfo Lutz Bacteriological Institute, has a mutation characterized by alterations in the Hemagglutinin protein.
Scientists the world over are concerned about mutation because it was this a mutation which causes the 1918 Spanish Flu to kill millions all over the world.
Read more about it on the ABS website
http://abs-cbnnews.com/world/06/17/09/brazil-finds-new-strain-h1n1-virus
50-th International Conference on Health & Science Communications ...
June 17 - 20
Featured Speakers
http://www.hesca.org/stlouis/?page_id=365
GENEVA - The World Health Organization declared a swine flu pandemic Thursday — the first global flu epidemic in 41 years — as infections in the United States, Europe, Australia, South America and elsewhere climbed to nearly 30,000 cases.
The long-awaited pandemic announcement is scientific confirmation that a new flu virus has emerged and is quickly circling the globe. WHO will now ask drugmakers to speed up production of a swine flu vaccine. The declaration will also prompt governments to devote more money toward efforts to contain the virus.
WHO chief Dr. Margaret Chan made the announcement Thursday after the U.N. agency held an emergency meeting with flu experts. Chan said she was moving the world to phase 6 — the agency's highest alert level — which means a pandemic, or global epidemic, is under way.
"The world is moving into the early days of its first influenza pandemic in the 21st century," Chan told reporters. "The (swine flu) virus is now unstoppable."
“However, we do not expect to see a sudden and dramatic jump in the number of severe and fatal infections,” she added.
Live coverage
http://www.msnbc.msn.com/id/21134540/vp/31250295#31250295
Philippine university suspends classes after student gets swine flu
http://www.monstersandcritics.com/news/health/news/article_1481106.php
Swine flu cases found in all 50 states in U.S.
Virus blamed for 17 deaths nationwide; actual infections may reach 200,000
http://www.msnbc.msn.com/id/30919716/
The virus, which spreads easily and causes mostly mild disease, has been diagnosed in 17,564 people in 64 countries, killing 115, according to the World Health Organization.
It was newly found this week in patients in Bulgaria, Vietnam and Jamaica.
Although H1N1 swine flu appears mild, it affects mostly older children and young adults, and experts worry it could change into a more dangerous form.
The Next Big Thing: Personalized Medicin
forbes.com/Adviser Soapbox
Jim Oberweis, The Oberweis Report, 05.28.09, 12:40 PM EDT
Following in the footsteps of tech, biotech and the Internet, genomics is shaping up to be the next investing boom.
The argument can be made that the surge of biotech development in the 1980s and 1990s was a result of increased government funding for programs like the National Institutes of Health, which bridged the gap between the academically possible and the commercially profitable.
From 1983 to 1993, the budget of the NIH increased 158%, rising from $4 billion to $10 billion. From 1993 to 2003, that budget increased another 163% to $27 billion. In addition to opening its purse strings, Congress also passed a series of laws that fostered the ability to profit from biotech discoveries.
In particular, the Bayh-Dole Act of 1980 permitted universities and small businesses to patent discoveries that evolved from NIH-funded research. Indeed, I think the biotech boom was a direct consequence of rising National Health Institute funding, cheap equity capital, and the ability to patent NIH-funded discoveries.
Under the Obama administration, NIH funding will explode once again, and there is a possibility that a similar wave of innovation will follow. In the last five years, under President Bush, NIH funding remained flat at $27 billion to $29 billion annually. The recently passed U.S. stimulus plan allocates $10.4 billion in additional NIH funding to be spent before September 2010, a windfall equaling roughly 30% of the annual budget.
In addition to the immediate flush of cash, the allocation demonstrates the new administration's commitment to public science funding. Research and academic institutions will benefit, as will the companies that support them.
No area is better positioned to benefit than genomics and personalized medicine. With knowledge of an individual's genetic makeup, doctors will prescribe drugs with far better understanding of their efficacy for that particular individual.
The cost of obtaining one's genotype through entire genome sequencing is plummeting: Sequencing cost $300 million in 2003, $1 million in 2007, $60,000 in 2008, is currently under $10,000, and will likely fall below $1,000 by the end of this year. Once below $300, gene sequencing will be cheap enough to be part of routine medical care. With costs this low, personalized medicine is just around the corner.
Just as with biotechs, making money from genomics could well prove elusive. Undoubtedly, genomics will produce an explosion of innovation. But finding the winners in advance is tricky business. Just like makers of picks and axes during the 18th-century California gold rush, makers of the tools that facilitate fast, cheap gene sequencing may be the safest bet.
http://www.forbes.com/2009/05/28/illumina-life-genomics-personal-finance-guru-insight-nih-genes.html
Swine Flu Is Spreading Wider Than Official Data Show
http://bloomberg.com/apps/news?pid=20601124&sid=agHVPFaC5R.M&refer=home
BACOLOD CITY, May 26 (PNA)
GenoMed, LaSalTech sign pact for preventive medicine venture
...Last month, GenoMed has announced that it has been in discussions to purchase Offshore HRM, a medical coding company which recently established a 200-person call center in Bacolod.
Moskowitz said GenoMed is engaged in two major activities, managing patients and doing research, and Offshore HRM will allow their company to manage patients on a large scale, and help them market to patients in the Philippines where there is an extremely high prevalence rate of diabetes.
Offshore HRM, which recently trained the Philippines’ first five medical coding professionals, will also recruit Filipino physicians and nurses and train them in GenoMed's algorithms to take care of paying patients. (PNA)
enjoy reading the story in full>>>>>>>>>>>
http://positivenewsmedia.net/am2/publish/Health_21/GenoMed_LaSalTech_sign_pact_for_preventive_medicine_venture.shtml
we can sweep the global market...>>>
If we can provide state-of-the-art healthcare to the poorest Filipino, we can sweep the global market.
— dwmoskowitz (@dwmoskowitz) May 18, 2009
Besides the Philippines, we're also in talks with Colombia...>>> http://twitter.com/dwmoskowitz
Looking To Test All -Time High
Outstanding Shares 249,506,760 as of Mar 31, 2008
-and at .04, the market cap is only $9,980,270.
GMED has had its ups and downs and even been as high as $.30+ ...
Now, we have even more intellectual property & more opportunities…
It's just a matter of time,
sam
…should break .016 easy based on accumulation.
…stock price was 1/2 cents a share in 2003, the year before we took in a little over $1.1 million in funding and stock price briefly soared up to 30+ cents…
Just as Microsoft brought us the Age of Personal Computing, GenoMed intends to be the leader in the Era of Genome-based Preventive Molecular Medicine.
Clinical Outcomes Improvement Program (COIP®).
http://www.thelatestmedicaltreatment.com/
>
Venture to introduce ‘molecular medicine’
BACOLOD — GenoMed, a Missouri-based "disease management" company, has partnered with Bacolod-based Internet services firm LaSalTech in a venture that will introduce preventive molecular medicine to the Philippines and later to other countries.
LaSalTech will serve as the "anchor partner" for a GenoMed Filipino venture that will include GenoMed, Inc., a public US company, and LaSalTech, Inc., a private Philippine company, a joint statement said.
David Moskowitz, GenoMed chief executive officer, arrived in Bacolod last week to sign a memorandum of understanding with LaSalTech represented by its chairman Bro. Rolando Dizon.
"The venture will include GenoMed’s protocols to keep diabetic and hypertensive patients off the kidney machine, a telecom company to help us market and deliver our medical advice by cellphone, call centers to answer patients’ questions in real time, and a generic drug company to offer the drugs we use at a price low enough for even the poorest Filipino to afford," Mr. Moskowitz said in a statement.
Globe Telecom, Inc. will help deliver GenoMed protocols by cellphone, the company executive said, while a "catastrophic hospitalization" insurance firm will also be a partner.
Talks with additional partners, including a generic drug company and a chain of pharmacies, will be held this week.
"In the future, we’d like to add a network of discount physicians, clinical laboratories, dentists and optometrists. Retail pharmacists could check patients’ blood pressures if doctors were too busy," Mr. Moskowitz said.
Mr. Dizon told reporters that LaSalTech is assisting GenoMed in the organization and management of the venture, including tapping potential partners.
GenoMed acknowledged that foreign companies like itself are limited by Philippine laws to a maximum of 40% ownership in any joint venture.
But the company has found many potential Filipino partners after only a month, Mr. Moskowitz noted.
Last month, GenoMed announced it was in talks to purchase Offshore HRM, a medical coding company which recently established a 200-man call center in Bacolod.
With GenoMed engaged in two major activities — managing patients and doing research — Offshore HRM will allow the company to manage patients on a large scale, and help market services to patients in the Philippines where there is an extremely high prevalence of diabetes, Mr. Moskowitz said. — Nanette L. Guadalquiver
19,530 new twitter followers in 30 days? Check it out http://twitter.com/dwmoskowitz
US swine flu deaths hit double-digits
http://www.myfoxchicago.com/dpp/news/national/dpg_Swine_Flu_US_Deaths_fc_20090521_2502191
The World Health Organization says swine flu has sickened more than 10,000 people in 41 countries and killed at least 80.
"This is a great day for GenoMed's shareholders. We finally get a chance to show our stuff in a nation of 90 million."
http://genomed.com/investor/dsp_investor.cfm
WHO seeks swine flu shot help for poor nations
Vaccine will still take months to produce, longer than expected, officials say
http://www.msnbc.msn.com/id/30823371/
Japanese junior high school students wear masks as precaution against swine flu during a school tour at the upper house of the Parliament in Tokyo, Japan, Tuesday, May 19, 2009.
Swine flu 'may infect two billion'
14 hours ago
Up to two billion people could be infected by swine flu if the current outbreak turns into a pandemic lasting two years, the World Health Organisation (Who) has said.
Who flu chief Keiji Fukuda said the historical record of flu pandemics indicates one third of the world's population gets infected in such outbreaks.
But he added: "This is a benchmark from the past. Please do not interpret this as a prediction for the future."
Mr Fukuda said: "If you look at past pandemics, it would be a reasonable estimate to say perhaps a third of the world's population would get infected with this virus."
With the current total population of more than six billion, that would mean an infection total of two billion, he said.
But he added the world has changed since pandemics of earlier generations, and experts are unable to predict if the impact will be greater or smaller.
"We don't really know," said Mr Fukuda. "This is a benchmark from the past. Please do not interpret this as a prediction for the future."
Chris Smith, a flu virologist at Cambridge University, said the two billion estimate was possible.
"That doesn't sound too outlandish to me for the simple reason that this is a very infectious virus," he said. "You're talking about a virus that no one in the population has seen before and therefore everyone is immunologically vulnerable.
"Therefore it's highly likely that once it starts to spread, people will catch it. And since the majority of the world's population are in contact with one another, you're going to get quite a lot of spread."
Stock Stations Thursday, May 7, 2009
http://www.microcapalliance.com/stations/default.asp?sid=64
elephants breed about every seven years ...
BioShield II Act SEC. 2151. REPORT TO CONGRESS.
Not later than 180 days after the date of enactment of this Act, the Director of the Centers for Disease Control and Prevention, in consultation with the Assistant Secretary for Medical Readiness and Response of the Department of Homeland Security and the Director of the National Institute for Allergy and Infectious Disease of the National Institutes of Health, shall submit a report to Congress that describes alternatives to traditional vaccines and anti-viral therapeutics for viral diseases, including negative immunomodulation compounds that partially suppress a macrophage-dependent innate immune response of an individual to viral pathogens, in order to decrease morbidity and mortality from an excessive immune response.
======================
Department Of Homeland Security
DHS Sets Guidelines For Possible Swine Flu Quarantines
Read the whole story: CBS News
http://www.cbsnews.com/blogs/2009/04/28/politics/politicalhotsheet/entry4975598.shtml
From Voice of America - "Dr. David Moskowitz is the CEO of GenoMed in St. Louis, Missouri. He describes GenoMed as a disease management company that prefers using readily available generic drugs. He says, 'We've been interested in the idea that viruses kill more because people overdo their immune response, rather than having too weak an immune response.' He says if that's the case, people's immune response can be reduced a few notches by using common blood pressure medication: 'They gently immunosuppress you, much more gently than, say, prednisone or steroids. So we've been using them for any viral disease we can get our hands on. We've been using it on West Nile (virus) in people and horses and birds since 2003 with good results – about a 70% treatment efficacy rate.'"
Statement by WHO Director-General, Dr Margaret Chan
29 April 2009
Swine influenza
Ladies and gentlemen,
Based on assessment of all available information, and following several expert consultations, I have decided to raise the current level of influenza pandemic alert from phase 4 to phase 5.
Influenza pandemics must be taken seriously precisely because of their capacity to spread rapidly to every country in the world.
On the positive side, the world is better prepared for an influenza pandemic than at any time in history.
Preparedness measures undertaken because of the threat from H5N1 avian influenza were an investment, and we are now benefitting from this investment.
For the first time in history, we can track the evolution of a pandemic in real-time.
I thank countries who are making the results of their investigations publicly available. This helps us understand the disease.
I am impressed by the work being done by affected countries as they deal with the current outbreaks.
I also want to thank the governments of the USA and Canada for their support to WHO, and to Mexico.
Let me remind you. New diseases are, by definition, poorly understood. Influenza viruses are notorious for their rapid mutation and unpredictable behaviour.
WHO and health authorities in affected countries will not have all the answers immediately, but we will get them.
WHO will be tracking the pandemic at the epidemiological, clinical, and virological levels.
The results of these ongoing assessments will be issued as public health advice, and made publicly available.
All countries should immediately activate their pandemic preparedness plans. Countries should remain on high alert for unusual outbreaks of influenza-like illness and severe pneumonia.
At this stage, effective and essential measures include heightened surveillance, early detection and treatment of cases, and infection control in all health facilities.
This change to a higher phase of alert is a signal to governments, to ministries of health and other ministries, to the pharmaceutical industry and the business community that certain actions should now be undertaken with increased urgency, and at an accelerated pace.
I have reached out to donor countries, to UNITAID, to the GAVI Alliance, the World Bank and others to mobilize resources.
I have reached out to companies manufacturing antiviral drugs to assess capacity and all options for ramping up production.
I have also reached out to influenza vaccine manufacturers that can contribute to the production of a pandemic vaccine.
The biggest question, right now, is this: how severe will the pandemic be, especially now at the start?
It is possible that the full clinical spectrum of this disease goes from mild illness to severe disease. We need to continue to monitor the evolution of the situation to get the specific information and data we need to answer this question.
From past experience, we also know that influenza may cause mild disease in affluent countries, but more severe disease, with higher mortality, in developing countries.
No matter what the situation is, the international community should treat this as a window of opportunity to ramp up preparedness and response.
Above all, this is an opportunity for global solidarity as we look for responses and solutions that benefit all countries, all of humanity. After all, it really is all of humanity that is under threat during a pandemic.
As I have said, we do not have all the answers right now, but we will get them.
Thank you.
-------------------------------
Related links
Watch the video [wmv, 7min 13 sec] http://whovideo.vo.msecnd.net/streaming/SWINE_FLU_PRESS_CONF_29APR2009_INTRO.wmv
Listen to the audio [mp3 57 Mb] http://whoterrance.vo.msecnd.net/mediacentre/audio/press_briefings/VPC_29APR2009swine_influenza_2.mp3
Influenza A(H1N1) - full coverage http://www.who.int/entity/csr/disease/swineflu/en/index.html
Current WHO phase of pandemic alert http://www.who.int/entity/csr/disease/avian_influenza/phase/en/index.html
International Health Regulations (IHR) http://www.who.int/entity/ihr/en/index.html
H1N1 Flu Update with HHS Sec. Kathleen Sebelius
http://www.pandemicflu.gov/secretarywebcast.html
Top US Researcher says Some Swine Flu Deaths may be due to Overactive Immune System.
By Joe DeCapua
Washington, DC
28 April 2009
The head of a US research firm says the deaths caused by the swine flu outbreak may be partly due to an overactive immune system – not a weakened one.
Dr. David Moskowitz is the CEO of GenoMed in St. Louis, Missouri. He describes GenoMed as a disease management company that prefers using readily available generic drugs. He says, "We've been interested in the idea that viruses kill more because people overdo their immune response, rather than having too weak an immune response." He says if that's the case, people's immune response can be reduced a few notches by using common blood pressure medication: "They gently immunosuppress you, much more gently than, say, prednisone or steroids. So we've been using them for any viral disease we can get our hands on. We've been using it on West Nile (virus) in people and horses and birds since 2003 with good results – about a 70% treatment efficacy rate."
Travelers at the Los Angeles International Airport, 27 Apr 2009
Moskowitz says the high immune response is caused by what's called a cytokine storm, a "tremendous outpouring of cytokines, of factors released by white cells that get other white cells really jazzed up." He says, "It's these white cells…that basically…turn the lung into a totally cellular organ like a liver, so it can't exchange gas anymore."
"People have always said with West Nile it's exactly the same group that dies, these young, healthy people from 20 to 50 that get hit the worst. So there's this old-school virology dogma that says you only get sick if your immune system is weak, and yet they've never been able to explain why healthy people cutting the grass are the ones who get West Nile every summer or why, in the 1918 flu epidemic it was young soldiers who all died. And the answer is, sure, if you're totally immunosuppressed, you're at risk for getting a viral infection, but the general population (that) actually dies from a viral disease are overdoing their immune response, not under doing it."
The researcher says there are anti-viral drugs that are effective against the Swine Flu virus but they're expensive and not widely available. The blood pressure drugs the company uses for West Nile haven't been shown yet to work for swine flu, so clinical trials are necessary. But he says these drugs are safe, cheap and available.
Feedback
We'd like to hear what you have to say. Let us know what you think of this report and other news and features on our website. Email your views about what is happening in Africa to: africa@voanews.com. Please include your name and phone number if you would like us to include your comments on our programs. Or, telephone us and leave a message. In the US, call: (202) 205-9942. After you hear the VOA greeting, press the number "30" and leave your opinion. We may use it on our daily broadcasts.
In time, people will see how this can help the world. Then this will fly again.
The 50th International Conference on Health & Science Communications
Featured Speakers
http://www.hesca.org/stlouis/?page_id=365
Hopefully GMED is a part of the action here
Obama Administration: Out With the 'Swine,' In With the 'H1N1 Virus'
http://blogs.abcnews.com/politicalpunch/2009/04/obama-adminis-5.html
$1.5 billion in emergency funding
Yeah, this could be huge if they urge Obama. Won't be pennies either.
GMED GOING TO .04-.05
THIS IS GETTING SERIOUS WITH THE DEATH OF A CHILD IN THE US!!!
WELL GMED CEO SAID THAT HE HAS THE CURE NOW USE IT
Swine Flu Public Service Announcements (PSAs)
CDC PSAs provide timely messages about what you can do to protect yourself and your family.
http://www.cdc.gov/swineflu/psa/
Swine Influenza (Flu)
Swine Flu website last updated April 29, 03:30 AM ET
U.S. Human Cases of Swine Flu Infection
(As of April 28, 2009, 11:00 AM ET) State # of laboratory
confirmed cases
California 10 cases
Kansas 2 cases
New York City 45 cases
Ohio 1 case
Texas 6 cases
TOTAL COUNT 64 cases
International Human Cases of Swine Flu Infection
See: World Health Organization
The human swine flu outbreak continues to grow in the United States and internationally. Today, CDC reports additional cases of confirmed swine influenza and a number of hospitalizations of swine flu patients. Internationally, the situation is more serious too, with additional countries reporting confirmed cases of swine flu. In response to the intensifying outbreak, the World Health Organization raised the worldwide pandemic alert level to Phase 4. A Phase 4 alert is characterized by confirmed person-to-person spread of a new influenza virus able to cause “community-level” outbreaks.” The increase in the pandemic alert phase indicates that the likelihood of a pandemic has increased.
CDC has activated its emergency operations center to coordinate the agency’s emergency response. CDC ’s goals are to reduce transmission and illness severity, and provide information to help health care providers, public health officials and the public address the challenges posed by this swine influenza virus. Yesterday, CDC issued a travel warning recommending that people avoid non-essential travel to Mexico. CDC continues to issue interim guidance daily on the website and through health alert network notices. CDC’s Division of the Strategic National Stockpile (SNS) is releasing one-quarter of its antiviral drugs, personal protective equipment, and respiratory protection devices to help states respond to the outbreak.
The swine influenza A (H1N1) virus is susceptible to the prescription antiviral drugs oseltamivir and zanamivir. This is a rapidly evolving situation and CDC will provide updated guidance and new information as it becomes available.
Lets hope the Obama administration gives him a chance to show the world what he can do.
GenoMed Urges President Bush to Avoid Costly Avian Flu Mistake
"We applaud President Bush for his concern, but his course of action is ill advised. Neither vaccines nor antiviral drugs work, and neither should be relied on ahead of our own anti-viral approach, which uses safe, already existing drugs present in every drug store on earth. Our approach, which is included in BioShield II, has already achieved over 80% treatment success in West Nile virus encephalitis and should be equally effective against avian influenza. All we need is the email address of a physician in Southeast Asia with a bird flu patient to test it."
http://www.redorbit.com/news/health/291730/genomed_urges_president_bush_to_avoid_costly_avian_flu_mistake/
Experts are nervous that, as a new strain, the swine flu will be harder to stop because there aren't any vaccines to fight it.
http://www.cnn.com/2009/HEALTH/04/28/regular.flu/index.html
What's the link to swine flu here?
the masks don't work anyway, a virus is smaller than the holes in the mask, common sense prevails, how could they work?
i live in mexico full time but i am near the san diego border
no problems here. i was sick 6 weeks ago in arizona with a severe viral infection viral influenza,got it in arizona.. i have not been sick like that except in 1968 era.i am still deaf in my right ear.it settled in my ears in 1968 too. .. i think i had the swine flu then , i think it came out of a u s government lab in arizona and sent to mexico city to put the screws on mexico..
the u s government has been hot and heavy over the last 6 months putting the screws to mexico imho. of course i also believe bush ordered the bombing of the twin towers too.
Look at the information box at the top for some information. I don't believe it is directly tied.
Followers
|
41
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1326
|
Created
|
11/27/01
|
Type
|
Free
|
Moderators |
Shares outstanding per the transfer agent 02/02/09: 221,170,711
04/27/09: Genomed Swine Flu Play?
http://www.cyperus.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/01-15-2004/0002090287&EDATE=
http://www.medicalnewstoday.com/articles/34202.php
http://www.medicalnewstoday.com/articles/10713.php
Annals Publishes GenoMed, Inc. Approach To Avian Influenza
http://www.biospace.com/news_story.aspx?NewsEntityId=34330
http://www.medicalnewstoday.com/articles/33141.php
GenoMed CEO Invited to Lecture at University of Chicago About Bird Flu
GenoMed’s WNV Treatment May Work for Avian Influenza
http://avianflu.futurehs.com/?p=804
Genomed - Preventive Molecular Medicine
Before posting on this board, please read the GMED BOARD LAW at the bottom of this iBox.
GenoMed, Inc.
9666 Olive Blvd.
Suite 310
St. Louis, MO 63132
USA
314-983-9933
Ticker Symbol: GMED
Website: http://genomed.com and http://www.thelatestmedicaltreatment.com/
GenoMed is a Next Generation DMtm company that uses medical genomics to improve patient outcomes. GenoMed is working to translate knowledge of medical genomics--the study of which genes cause disease--into clinical practice. We combine biotechnology with Disease Management (DM). We develop new and better drugs, we use existing drugs for new disease indications, and we uncover disease before symptoms arise. By studying disease genes, we hope to make medicine more proactive and disease prevention more effective.
Our goal is nothing short of a medical revolution: we aim to change the way medicine is practiced. Just as Microsoft brought us the Age of Personal Computing, GenoMed intends to be a leader in the Era of Genome-based Preventive Molecular Medicine. Indeed, we believe that our patent-pending ACE inhibitor treatment, if widely applied, could save 50% of healthcare costs worldwide over the next decade.
per http://www.thelatestmedicaltreatment.com/,
"Our goal is nothing short of a medical revolution: we aim to change the way medicine is practiced. Instead of waiting for symptoms to develop, we intend to diagnose disease before any signs are visible. Just as Microsoft brought us the Age of Personal Computing, GenoMed intends to be the leader in the Era of Genome-based Preventive Molecular Medicine."
12/08:Is the Era of Personalized Medicine (Almost) Really Here?
"...President-Elect Obama is promising to throw his weight behind personalized medicine in the upcoming administration says AP"
"...while in the Senate, Obama sponsored a personalized medicine bill himself that promoted the R&D necessary to develop genetic tests for certain drugs and to develop a "biobank" of information for researchers and federal funding for this research as well, says AP."
source: http://blog.bioethics.net/2008/12/is-the-era-of-personalized-medicine-almost-really/
"Master" Disease Gene/Fountain of Youth?
GenoMed has discovered and applied for patent protection on a treatment that could have wide-ranging use for over 150 common diseases that currently carry a dismal prognosis. These include diabetes and its complications (which affects 20 million in the United States alone), high blood pressure and its complications (which affects 60 million in the U.S.); emphysema and other smoking-related diseases; and many other serious diseases, including infection with HIV and progression to AIDS, common solid cancers such as lung, colon, pancreas, liver, and kidney; cancers of the blood-stream such as chronic leukemias, multiple myeloma, and lymphomas; and immune-mediated diseases such as multiple sclerosis, degenerative joint disease (osteoarthritis) and rheumatoid arthritis.
GenoMed has found that over-activity of a single enzyme, angiotensin I-converting enzyme ("ACE"), may be behind these diseases. The logical treatment is effective inhibition of the ACE enzyme, using the correct dose of the correct ACE inhibitor. As a class, ACE inhibitors have been in widespread use since the 1970's, and have a very well-known safety profile. The company has so far had dramatically positive results in the following diseases:
1. Chronic kidney failure due to adult-onset diabetes
2. Chronic kidney failure due to high blood pressure
3. Poor circulation due to high blood pressure
4. End-stage emphysema
5. Psoriasis
GenoMed Completes First Version of Healthchip(r) for Cancer Prediction
ST. LOUIS, April 20, 2005 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management company, said today that it has constructed a Healthchip® which may serve as an early warning system for the top six common cancers in whites: breast, colon, lung, ovarian, pancreatic, and prostate.
GenoMed's Healthchip® is made up of many single nucleotide polymorphisms (SNPs). In internal testing, the Healthchip® correctly identified the type of cancer in 85% of cases. None of the normals were misdiagnosed. More testing is required to confirm these results.
The well known breast cancer genes, BRCA1 and BRCA2, account for only 5% of breast cancers in white women. GenoMed's SNPs may pick up the remaining 95% of sporadic breast cancer cases in white women, i.e. in women without a strong family history of breast cancer.
Said Dr. David Moskowitz, GenoMed's chairman and chief executive officer, "It's important for any screening test to have as few false positives as possible. GenoMed's Healthchip® currently has none."
The test for mutations in the BRCA1 and BRCA2 genes costs about $1,200, has been available for about a decade, and has been reimbursed by a handful of insurance plans for the past few years. GenoMed's test is currently available for research purposes only, and is not yet reimbursable by any health plan. Please contact Dr. Moskowitz at dwmoskowitz@genomed.com to inquire about GenoMed's testing program.
SEC Filings - GenoMed files
http://www.b2i.us/profiles/investor/sec.asp?BzID=571
GenoMed has the solution to the coming pandemic.
April 19, 2006 - GenoMed to Offer Free Mumps Trial http://tools.thestreet.com/rmy/quotes.html?pg=qcn&guid={3D6172DA-7BE1-495A-9696-E13B4F9E8A9A}&am....
February 1, 2006 - GenoMed's Formula for Better Healthcare at Half the Price = GenoMed + President Bush's HSAs
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=14065&GoTopage=1&am....
January 11, 2006- Turkish Brothers With Virus But No Symtoms Confirm GenoMed's Approach to Bird Flu
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=13849&GoTopage=1&am....
December 29, 2005 - Q & A page. Many of us find it incredible that your solution to the Avian flu problem has not been accepted in mainsteam circles. We are sure it will be in thefuture. Have you been able recently to make progress in this area?
http://www.b2i.us/profiles/investor/QAForum.asp?BzID=571
November 14, 2005 - 'Cytokine Storm' Paper Confirms GenoMed's Approach to Avian Flu
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=12769&GoTopage=1&am....
September 16, 2005 - GenoMed's WNV Treatment May Work for Avian Influenza; GenoMed Tries to Help President Bush Avoid Avian Flu Mistake
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=11695&GoTopage=2&am....
scientists say bird flu provokes an excessive immune reaction (Reuters)
Investor Relations:
David Moskowitz MD, MA(Oxon.), FACP
Chief Medical Officer
dwmoskowitz@genomed.com
Phone: (314) 983-9933
Fax: (314) 983-9939
News:
June 26, 2006- GenoMed Can Explain Link Between West Nile, Diabetes/Hypertension
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=16056&GoTopage=1&am....
June 21, 2006- GenoMedGenoMed CEO Invited to Lecture at University of Chicago about Bird Flu
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=15953&GoTopage=1&am....
June 5, 2006- GenoMed, West Nile Virus, and Counting Crows
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=15818&GoTopage=1&am....
May 2, 2006- MO Rep. Mott Oxford Congratulates GenoMed on Reversing Kidney Failure
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=15384&GoTopage=1&am....
April 12, 2006- GenoMed Awarded Second Patent, for Avoiding Dialysis in Acute Kidney Failure
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=15006&GoTopage=1&am....
March 9, 2006- GenoMed Agrees to Distribute Healthcare to India for Under $150 Per Patient Per Year
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=15006&GoTopage=1&am....
March 1, 2006- GenoMed Awarded Second Patent, for Avoiding Dialysis in Acute Kidney Failure
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=14428&GoTopage=1&am....
February 23, 2006- GenoMed Trial Results: Multiple Sclerosis—From Two Relapses a Year to None in 16 Months
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=14330&GoTopage=1&am....
February 22, 2006- GenoMed Trial Results: Sickle Cell Disease—From Daily Pain to None
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=14329&GoTopage=1&am....
February 21, 2006- GenoMed Trial Results: HIV--Viral Load Goes to Zero
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=14327&GoTopage=1&am....
November 28, 2005 - GenoMed Considers Offering Low-Cost Health Insurance to America's Uninsured
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=13128&GoTopage=1&am....
November 14, 2005 - 'Cytokine Storm' Paper Confirms GenoMed's Approach to Avian Flu
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=12769&GoTopage=1&am....
October 28, 2005 - GenoMed Scores 14th Victory Treating Neuroinvasive West Nile Virus in Humans
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=12531&GoTopage=2&am....
September 16, 2005 - GenoMed's WNV Treatment May Work for Avian Influenza; GenoMed Tries to Help President Bush Avoid Avian Flu Mistake
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=11695&GoTopage=2&am....
July 26, 2005 - GenoMed Submits 50th Provisional Patent
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=10830&GoTopage=2&am....
July 25, 2005 - GenoMed's Observation of Major Racial Difference in Prostate Cancer Confirmed
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=10805&GoTopage=2&am....
July 13, 2005 - GenoMed Joins International Disease Management Alliance
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=10498&GoTopage=2&am....
June 29, 2005 - GenoMed CEO Testifies Before Missouri Medicaid Reform Commission
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=10216&GoTopage=2&am....
June 24, 2005 - GenoMed's WNV Treatment Abruptly Stopped, Patient Deteriorates
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=10147&GoTopage=3&am....
June 21, 2005 - GenoMed's Method to Prevent Most Kidney Dialysis Featured on IKIDNEY.COM
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=9973&GoTopage=3&....
June 16, 2005 - GenoMed Treats Its First Presumptive West Nile Virus Patient of 2005
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=9944&GoTopage=3&....
June 14, 2005 - GenoMed to be Awarded Second Patent, for Treating Acute Kidney Failure Without Dialysis
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=9926&GoTopage=3&....
June 07, 2005 - GenoMed Announces 3rd Year of its West Nile Virus Trial; Now Part of BioShield II
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=9862&GoTopage=3&....
May 26, 2005 - GenoMed to be Awarded First Patent: Hastening Lung Maturation in Newborns.
http://biz.yahoo.com/prnews/050526/cgth017.html?.v=10
May 03, 2005 - BioShield II Specifically Mentions GenoMed's Antiviral Approach.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=8988&GoTopage=4&....
April 20, 2005 - GenoMed Completes First Version of Healthchip(r) for Cancer Prediction.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=9175&GoTopage=1&....
April 07, 2005 - GenoMed Offers Treatment to Combat Effects of Smoking.
http://tools.thestreet.com/rmy/quotes.html?pg=qcn&guid={819BED6A-86DF-4818-A5AD-D832773CD614}&am....
April 05, 2005 - GenoMed Speaks Today at 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care
http://tools.thestreet.com/rmy/quotes.html?pg=qcn&guid={D1BC492A-545E-4CC5-9876-B2C310E49644}&am....
Mar. 31, 2005 - GenoMed, Inc. Issues Clarification
GenoMed, Inc. (Pink Sheets: GMED) has been advised that one or more Internet websites are recommending the purchase of the Company's stock, and that unsolicited electronic mail has been circulated encouraging the purchase of the Company's stock. The Company is not responsible for, and is unaware of the source of, such Internet activity and makes no comment about the accuracy of such communications. The Company's management does not comment on research reports or rumors concerning the Company's activities or stock price.
Mar. 24, 2005 - GenoMed's Dr. David Moskowitz Featured on Wall Street Reporter
http://www.wallstreetreporter.com/profiles/GenoMed.html
Mar. 10, 2005 - GenoMed, Inc. Says New Medicare Legislation May Accelerate Acceptance of Its Therapy.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=8721&GoTopage=1&....
Mar 03, 2005 - GenoMed Finds Thousands of Cancer-Associated Genotypes.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=8643&GoTopage=1&....
Feb 23, 2005 - GENOMED THERAPY COULD REDUCE HELATHCARE COSTS.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=8521&GoTopage=1&....
Feb 15, 2005 - GENOMED INC. FILES PATENT APPLICATION Company Identifies Two Additional Cancer-Related Genes.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=8280&GoTopage=1&....
Jan 20, 2005 - West Nile Virus Encephalitis Victim's Family Wants to Increase Public Awareness of GenoMed's Clinical Trial.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=7901&GoTopage=1&....
Jan 13, 2005 - GenoMed Finds Two Genes Linked to Common Cancers.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=7910&GoTopage=1&....
Dec 13, 2004 - UC Irvine Researcher Confirms GenoMed’s Patent-Pending Discovery: ACE is Major Aging Gene, ACE Inhibition is Partial “Fountain of Youth”
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=7652&GoTopage=1&....
July 13, 2004 - GenoMed and Italian NIH to Collaborate in Finding a Cure for Bird Flu in Poultry
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=6534&GoTopage=7&....
July 06, 2004 - GenoMed Applies for Listing on American Stock Exchange
Recent Publications
1. From Pharmacogenomics to Improved Patient Outcomes: Angiotensin I-Converting Enzyme as an Example
http://www.genomed.com/pdf/diabetes.technology.therapeutics.pdf
2. Is Angiotensin I-Converting Enzyme a "Master" Disease Gene?
http://www.genomed.com/pdf/is.angiotensin.pdf
3. Is "Somatic" Angiotensin I-Converting Enzyme a Mechanosensor?
http://www.genomed.com/pdf/Is.ACE.a.Mechanosensor.pdf
4. Pathophysiologic Implications of Angiotensin I-Converting Enzyme as a Mechanosensor: Diabetes
http://www.genomed.com/pdf/Pathophysiologic.pdf
5. Why AT1R blockade makes sense for SARS
http://www.genomed.com/pdf/AT1RSARS.pdf
6. The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
http://www.genomed.com/pdf/ACE_vertebrate_pathophysiology.pdf
****GMED BOARD LAW: The main objective for this moderated board is to keep it free of posts which do not add value to the discussion of the stock, while keeping the board balanced, clean, on-topic with due diligence kept up to date. All posts here should stay focused on GMED, along with any other information which pertains to or affects GMED, i.e. competition, FDA guidance, current events, T/A analysis. Pro and con debate is encouraged as long as the opinions are kept on a mature level, with the omission of personal jabs.
ZERO TOLERANCE LEVEL FOR PERSONAL ATTACKS, PESONAL ISSUES, POLITICAL INNUENDO, SPAM, MULTIPLE ALIASES, DUPLICATE POSTS OF THE SAME SUBJECT MATTER, REDUNDANCY, OBVIOUS BASHING, OBVIOUS BOARD DISRUPTION TACTICS, IRRELEVANT OFF-TOPIC SUBJECT MATTER, ADVERTISING, ARGUING.
POSTS WILL BE REMOVED WITHOUT DEBATE OR QUESTION. PLEASE DON'T FEED THE ANIMALS!!!!
If moderation of this nature offends you, then this board is not for you.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |